Le gène HIC1 a été caractérisé comme un gène suppresseur de tumeur situé en 17p13.3, une région hyperméthylée ou délétée dans de nombreux cancers. HIC1 code un répresseur transcriptionnel caractérisé par plusieurs domaines fonctionnels. Au niveau de la région centrale, se retrouve un motif conservé MK314HEP important pour la répression des gènes cibles de HIC1 au sein duquel la Lysine 314 est soit SUMOylée soit acétylée. HIC1 est au centre de boucles de régulation complexes mettant en jeu le gène suppresseur de tumeurs TP53 et la désacétylase SIRT1. En réponse aux cassures double brin de l’ADN (DSBs) non réparables, HIC1 réprime l’expression de SIRT1 favorisant ainsi l’apoptose médiée par p53. De plus, dans ces conditions on observe une augmentation de la SUMOylation de la Lysine 314 de HIC1 de manière dépendante de la kinase ATM, ce qui favorise l’interaction avec le complexe répresseur NuRD. HIC1 joue également un rôle dans la réparation des DSBs. Nous avons montré que la SUMOylation de HIC1 n’était pas nécessaire pour la réparation des DSBs. Grâce à une analyse de protéomique, nous avons identifié un site potentiel de phosphorylation LS694QG par des kinases de la famille PIKK. Ainsi, nous avons montré dans des fibroblastes humains BJ-hTERT, que la protéine HIC1 est rapidement phosphorylée sur la Sérine 694 par la kinase ATM en réponse aux DSBs. De plus, par la technique de « Comet Assay » nous avons montré que cette phosphorylation est importante pour la réparation.HIC1 jouerait donc un double rôle dans la réponse aux dommages à l’ADN : soit il agirait en tant que répresseur transcriptionnel dans le cas de DSBs non réparables, soit il faciliterait la réparation des DSBs. / The tumor suppressor gene HIC1 is located in 17p13.3, a region frequently hypermethylated or deleted in many cancers. HIC1 encodes a transcriptional repressor characterized by several functional domains. In the central region, the conserved MK314HEP motif is an Acetylation/SUMOylation switch motif centered on K314 which regulates the recruitment of MTA1, a component of NuRD repressor complexes. A regulatory feedback loop between HIC1, SIRT1 and P53 has been described. HIC1 directly represses the transcription of SIRT1, thereby modulating P53-dependent DNA damage responses. Furthermore, after induction of non-repairable DSBs (DNA Double Strand Breaks), we observed a SUMOylation increase dependant on the ATM kinase. Moreover, HIC1 also plays an important role in the repair of DSBs. Furthermore, comet assays with a non SUMOylable HIC1 point mutant (E316A) demonstrated that SUMOylation of Lysine K314 is dispensable for DNA repair. In addition, upon induction of repairable DSBs, we have identified by proteomic analyses, a potential phosphorylation site “LS694QG” for the PIKK family kinases ATM and DNA-PKcs. Moreover, we have shown that HIC1 is rapidly phosphorylated by ATM upon DNA damage induction in normal human fibroblasts (BJ-hTert). Furthermore, comet assays with a non phosphorylable HIC1 point mutant have shown that this phosphorylation is very important for the contribution of HIC1 to the repair of DSBs. Thus, HIC1 plays different role during the DNA damage response to DNA double strand breaks depending on their intensity.

Es soll untersucht werden, inwieweit sich das auf dem Gebiet der weitverkehrsnetzeetablierte ATM für den Einsatz im LAN eignet.

Ataxia-telangiectasia mutated kinase (ATM), a serine/threonine kinase primarily located in the nucleus, is typically activated in response to DNA damage. Individuals with mutations in ATM gene develop a disease called Ataxia telangiectasia (AT). These individuals are more susceptible to ischemic heart disease and metabolic disorder. Our lab has previously shown that ATM plays a critical role in β-adrenergic receptor (β-AR) - and myocardial infarction (MI)-stimulated myocyte apoptosis and cardiac remodeling. This study tested the hypothesis that ATM plays a critical role in cardiac autophagy and glucose metabolism following MI and ischemia, respectively. Early during MI (4 hours after its onset) and 4 hours post-treatment with ATM inhibitor KU-55933, ATM deficiency resulted in autophagic impairment in the heart and in cardiac fibroblasts, respectively. Such autophagic changes in the heart and in cardiac fibroblasts associated with the activation of GSK-3β and mTOR, and inactivation of Akt and AMPK. ATM deficiency also augmented autophagy in the infarct region of the heart 28 days post-MI as well as in cardiac fibroblasts treated with ATM inhibitor KU-55933 for 24 hours. Autophagic changes in the infarct region during ATM deficiency associated with enhanced Akt, Erk1/2, and mTOR activation. Additionally, the lack of ATM accelerated glycolysis and gluconeogenesis and augmented TCA cycle metabolism under non-ischemic conditions. Following a 20 minute global ischemic period, the glycolytic pathway, not the gluconeogenic pathway, was down-regulated during ATM deficiency which was found to be associated with alterations in TCA cycle metabolism. Such metabolic rearrangements associated with changes in the phosphorylation of Akt, GSK-3β, and AMPK alongside alterations in Glut4 protein expression. Thus, ATM deficiency impairs autophagy early after the onset of MI and in cardiac fibroblasts treated with ATM inhibitor KU-55933 for 4 hours. In contrast, ATM deficiency appears to augment autophagy late post-MI in the infarct region of the heart and in cardiac fibroblasts treated with ATM inhibitor KU-55933 for 24 hours. Lack of ATM alters glucose and TCA cycle metabolism with and without ischemia. Such findings implicate ATM as a key player in autophagic changes in the heart in response to MI as well as in glucose metabolism under non-ischemic and ischemic conditions.

Ataxia Telangiectasia Mutated (ATM) gene helps to repair DNA damage and that increased cancer risks are associated with having a mutation in an ATM gene. ATM gene is newer compared to other known hereditary cancer genes. We present a rare care of 66-year-old female with extensive personal and family history of breast and pancreatic cancer had negative imaging surveillance until recent systemic imaging showed new pancreatic head 2.5x2.5 cm mass. Endoscopic ultrasound confirmed invasion of superior mesenteric vein with near confluence. No regional adenopathy was seen. She was felt to be borderline resectable and neoadjuavant chemotherapy was planned. She had a personal history of right breast cancer diagnosed in 1998 status post lumpectomy and axillary lymph node dissection and adjuvant chemotherapy with CMF regimen x 5 cycles and radiation therapy and endocrine therapy with tamoxifen for 5 years. In 2011 she was also diagnosed with rectal well to moderately differentiated adenocarcinoma status post abdominoperitoneal resection on 3/15/2011, 36 lymph nodes were negative, but the surgical circumferential radial margin was positive. She underwent adjuvant radiation therapy with total dose of 45 Gy. There was recurrence in vaginal and bladder wall adenocarcinoma in 2014 for which patient underwent an anterior exenteration. Pathology felt this was endocervical origin of malignancy and patient received megace therapy for 3 years based on hormone receptor positive status. For new diagnosis of pancreatic adenocarcinoma, she was started on Gemcitabine and Abraxane chemotherapy. Given extensive personal and family history of malignancy, she was referred to genetic counsellor. Hereditary cancers panel at invitae laboratory was positive for a heterozygous pathological variant in the ATM gene deletion (exons 62-63). ATM gene is associated with an increased risk for autosomal dominant breast, pancreatic and prostate cancer. Close relatives (children, siblings, and each parent) have up to a 50% chance of being a carrier of this variant. It is essential for treating physicians to educate patients and family members on the risk for subsequent malignancies.

Inhibiting inflammatory processes or eliminating inflammation represents a logical role in the suppression and treatment strategy of cancer. Several studies have shown that anti-inflammatory drugs (NSAIDs) have promise as anticancer agents while reducing metastases and mortality. NSAIDs are seriously limited by side effects and their toxicity, which can become cumulative with their long-term administration for chemoprevention. The huge development in nanotechnology allows the drugs to exhibit novel and significantly improved properties compared to the large particles of the respective bulk compound, leading to more targeted therapy and reduced dosage. The overall aim of this thesis is to add to our understanding of cancer prevention and treatment through studying the genotoxicity mechanisms of NSAIDs agents in lymphocytes. In this study, the genotoxicity mechanisms of NSAID in bulk and nanoparticles forms a strategy to prevent and minimise the damage in human lymphocytes. Aspirin nano (ASP N) caused a significant decrease in deoxyribonucleic acid (DNA) damage compared to aspirin bulk (ASP B). Also, ibuprofen nano (IBU N) showed a significant reduction in DNA damage compared to ibuprofen bulk (IBU B). Micronuclei (MNi) decreased after ASP N, ASP B and IBU N in prostate cancer patients and healthy individuals, and the ibuprofen bulk showed a significant increase of MNi formation in lymphocytes from healthy and prostate cancer patients when compared to untreated lymphocytes from prostate cancer patients. In order to study the geno-protective properties of these drugs, the protective effect of NSAIDs and the quantification of the DNA repair capacity in lymphocytes was studied. ASP N was found to increase the DNA repair capacity and reduced the reactive oxygen species (ROS) formation significantly more than ASP B. Finally, the role of NSAIDs on some key regulatory signal transduction pathways in isolated lymphocyte cells was investigated by studying their effect on ataxia-telangiectasia-mutated kinase (ATM) and ataxia-telangiectasia and Rad3-related kinase (ATR) mRNA. ATM mRNA significantly increased after treatment with ASP B, ASP N and IBU N. ATR expression also increased after treatment with IBU B and IBU N, but was only significant with IBU N. These findings indicate that a reduction in particle size had an impact on the reactivity of the drug, further emphasising the potential of nanoparticles as improvement to current treatment options.

No description available.

<p><h2> </h2></p> <p>Telomeres are protein-DNA complexes found at the ends of human chromosomes. The function of telomeres is to protect chromosome ends from being recognized as damaged DNA. This protection is essential in preventing the erosion of telomeres, which has been shown to lead to genomic instability, a hallmark of cancer and aged cells. Precise regulation of telomere length and function is crucial to cell survival, and defects in this regulation are related to tumorigenesis and aging related disorders. The proteins that bind telomere DNA play an indispensable role in telomere maintenance. TRF1, <em>t</em>elomere <em>r</em>epeat binding <em>f</em>actor 1, is a protein that directly binds to mammalian telomeric DNA and participates in regulating telomere length. Post-translational modifications, such as phosphorylation, have been shown to modulate TRF1 function. The results presented here demonstrate that two phosphorylation sites on TRF1, S367 and T371, are involved in regulating the function and localization of TRF1. TRF1 S367 is phosphorylated by ATM, and this phosphorylation removes TRF1 from telomere DNA and directs TRF1 to sites of proteasome degradation. On the other hand, the phosphorylation of TRF1 at T371 prevents the association of TRF1 with telomere DNA but also protects TRF1 from degradation. We have demonstrated that the phosphorylation of T371 by CDK1 is important for the resolution of sister chromatids in mitosis. In interphase cells, in response to the induction of DNA damage, TRF1 phosphorylated at T371 is recruited to sites of damage and is involved in promoting efficient homologous recombination and in conferring checkpoint activation and cell survival. The work presented within this thesis sheds light on the regulation of TRF1 function by phosphorylation events and reveals novel functions of TRF1.</p> / Doctor of Philosophy (PhD)

DNA damage response (DDR) maintains genome integrity through checkpoint activation and lesion repair. While ATM and ATR are essential in DDR, mechanisms regulating their activation remain unclear. BMI1 is a component of the polycomb repressive complex 1 (PRC1), and contributes to PRC1’s E3 ubiquitin (E3-Ub) ligase activity though binding the catalytic subunit RING2. BMI1 binds RING2 through its ring finger (RF) domain. The E3-Ub ligase activity contributes to BMI1-deirved facilitation of the homologous recombination-based repair of DNA double-stranded breaks (DSBs). My research demonstrates that BMI1 reduces ATM and ATR activation during DDR. DSBs and single-strand DNA (ssDNA) lesions respectively activate ATM and ATR. ATM subsequently phosphorylates CHK2 at threonine 68 (CHK2pT68) and induces G2/M arrest. ATR produces CHK1pS345 and S-phase arrest. Both kinases phosphorylate histone H2AX at serine 139 (γH2AX) to prepare for lesion repair. Hydroxyurea initiates DDR via producing ssDNA lesions, and increases ATR activation (phosphorylation of T1989/ATR pT1989), CHK1pS345, γH2AX, and S-phase arrest. These events were significantly reduced and enhanced following the respective BMI1 overexpression and BMI1 knockdown in MCF7 and DU145 cells. BMI1 also displays similar effects towards ATM during DDR induced by etoposide-caused DSBs. Activation of ATM and ATR requires the formation of the ATM-NBS1 and ATR-TOPBP1 complexes. We observed that BMI1 interacted with NBS1 or TOPBP1. Deletion of the RF domain from BMI1 did not affect the associations and also had no effects on BMI1’s activity in reducing ATM activation and ATR-mediated CHK1 pS345. Collectively, our research suggests that BMI1 attenuates ATM and ATR signaling independently of the E3-Ub ligase activity. Genotoxic treatments elicit DDR in cells that are directly exposed and also in cells that are not exposed, a phenomenon known as bystander effect (BE). However, it remains unclear what mediates the BE. Microvesicles are small membrane-enclosed sacks that are shed from donor cells and communicate specific messages to recipient cells. We demonstrated that microvesicles isolated from cells treated with etoposide and ultraviolet induced BE in recipient cells. Neutralization of microvesicles through annexin V reduced the microvesicles-associated BE. / Thesis / Doctor of Philosophy (PhD)

One of the most important components of any wireless network is the medium access control protocol. This research deals with wireless ATM (WATM) medium access control (MAC) protocol. Conventional studies concerning WATM have focused mainly on variations of the time-division-multiple-access (TDMA) method for the wireless aspect of WATM networks. However, there are many advantages that the direct-sequence code-division-multiple-access (DS-CDMA) air-interface method has, such as inherent robustness against multipath fading, better resilience against security infringement attempts, and greater overall capacity compared to the TDMA method as proven in the cellular telephone industry. The main reason behind the relatively broader support for the TDMA method is that the source bit rate is generally higher compared to the DS-CDMA method since the maximum data rate per mobile unit is limited by the processing gain of a traditional DS-CDMA method. In this research, the problem of limited data rate often associated with a DS-CDMA air-interface is alleviated by employing the recently conceived multi-coded DS-CDMA as the primary air-interface, which is known to achieve maximum data rate per mobile unit comparable to applications employing TDMA. The focus of this research is on overcoming periods of significant deterioration of the wireless channel by adaptively employing bit combining. A MAC protocol called Adaptive Parallel Multiple Sub-stream CDMA (APMS-CDMA) is proposed to alternate between normal and ¡°rake-in¡± mode to deal with the often hostile environment of a WATM network. Although the context in which this research effort was conducted was a wireless ATM network environment, the protocol and techniques developed here can be applied to other infrastructure wireless systems using multi-code CDMA as their air-interface. Further, independent of the air-interface technique employed, other wireless systems can benefit from the channel estimation and the traffic management techniques used in this research effort. / Ph. D.

No / Visinet is a trans-European 3D collaborative design project that brings together computer scientists, application developers, design specialists, and users in the context of shared environments supported by ATM networks. Experiments and trials have been conducted for the key application domains of architectural and industrial design. Different types of virtual representation and computer-supported collaborative work are applied to real-life projects between partners at different locations in Europe. Measurements of network requirements have enabled cost/benefits to be quantified. Measurements of user satisfaction and speed of completion of the design to product cycle have also been made, resulting in a greater understanding of the ways in which collaborative design environments linked by high-speed networks affect this cycle. Additional experiments are currently being conducted on the way in which an ATM backbone between principal partners in a project can be complemented with ISDN links to partners in a local area.